And yet the stock keeps falling or least doesn't go up very much. Wonder why? My answer is no one believes much of anything on your list will actually generate revenue much less profit. That's not to it won't, but that the market has decided to wait and see proof knowing it's given up much of the upside by waiting.
I was glad to see the new updated corporate presentation. I like our chances! https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e. ***PHASE 3, close to EUA or close to market (13 programs) 1. Abivertinib NSCLC NDA filed China 2. Abivertinib NSCLC ph.3 completed US 3. PD-L1 SCLC partnered 4. Erbitux biosimilar 5. Xolair biosimilar 6. Remicade biosimilar(approved in China. SRNE holds ROW rights!) 7. SP-102 sciatica 8. RTX Osteo Arthritis 9. RTX cancer pain 10. Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA 11. Covi-Trace EUA application 12. Sofusa Enbrel 13. Cynviloq (part of PSS lawsuit) ***PHASE 2 (13 programs) 1. Seprehvir Oncolytic virus 2. Covi-MSC EUA potential 3. Covi-AMG EUA potential DOD CRADA 4. COVIDROPS EUA potential DOD CRADA 5. Covi-Track EUA pre-validation DOD CRADA 6. PD-L1 partnered 7. Herceptin delivery partnered 8. Abivertinib Lymphoma 9. Abivertinib Covid 19 EUA potential as soon as August 10. Abivertinib prostate cancer ph.2 IND 11. Abivertinib Lupus ph.2 IND 12. Abivertinib hairy cell leukemia 13. CD47 partnered ***PHASE 1, IND filed or pre-IND (46+ programs) 1. Seprehvec Oncolytic Virus 2. CD 38 CAR-T ph.1 3. CEA CAR-T ph.1 4. CD38 DAR-T ph.1 5. BCMA DAR-T pre-IND 6. PD-L1(C/DAR-T) pre-IND 7. CyCART-19 partnered 8. Covi-GeneMab pre-IND $34 million DARPA funding 9. PD1-GeneMab pre-IND 10. ERT (Enzyme Replacement Therapy) several pre IND programs 11. IL2Teff pre-IND 12. IL2Treg pre-IND 13. Sofusa anti-PD1 and anti-CTLA4 14. TNF-a (Enbrel) ph.1 15. CTLA-4 (Yervoy) 16. CD47 ph.1 basket trial partnered 17. TROP2 IND granted in China...partnered. 18. BCMA ADC pre-IND 19. ROR1 ADC pre-IND 20. CD25 ADNAB pre-IND 21. CD20 ADNAB (Rituxan) IIT-ph.1 22. VEGF(Avastin) ADNAB IIT-ph.1 23. PD-L1 ADNAB pre-IND 24. VEGFR2 ADNAB pre-IND 25. CBD immune diseases pre-IND 26. CBD insomnia pre-IND 27. CBD Parkinsons pre-IND 28. CBD CNS diseases pre-IND 29. PD-L1 CAR-NK partnered 30. CD38 CAR-NK to be partnered 31. CD38 ADC AL Amyloidosis 32. AC0058 ph.1b lupus 33. AC0058 pre-IND MS 34. AC0939 pre-IND CNS indications 35. A166 HER2 ADC phase 1 36. Karolinska off-the-shelf DAR-NK pre-IND 37. Covid mRNA vaccine(Sofusa delivery) 38.low cost C1 based multivalent vaccine(rights to 60% of world population) 39. Salicyn-30 oral antiviral 40.MP18 oral antiviral MPro inhibitor 41.Combination oral antiviral drug cocktail 42.RESPISTIX Combination Covid/seasonal flu tests 43.Combination Covid/seasonal flu vaccine 44 advanced Animal Health subsidiary 45. 1,000,000+ small molecule library 46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20.4 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!